Proceedings of the National Academy of Sciences of the United States of America.
In January 2021, Pfizer said it had finished enrolling 2,259 children aged between 12 and 15 years to study the vaccine's safety and efficacy.
By mid-December 2020, Pfizer had agreements to supply 300 million doses to the European Union, 120 million doses to Japan, 40 million doses 10 million before 2021 to the United Kingdom, 20 million doses to Canada, an unspecified number of doses to Singapore, and 34.